Immunohistochemical analysis for histopathological subtypes in pediatric medulloblastomas

Pathology International

Volumn 53, Issue 2, 2003, Pages 67-73

  Son, Eun Ik ^a   Kim, Il Man ^a   Kim, Dong Won ^a   Yim, Man Bin ^a   Kang, Yu Na ^a   Lee, Sang Sook ^a   Kwon, Kun Young ^a   Suh, Seong Il ^a   Kwon, Taeg Kyu ^a   Lee, Jung Jeung ^a   Kim, Dong Sug ^b   Kim, Sang Pyo ^a  

^a Keimyung University School of Medicine   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

Anaplasia; Histopathology; Immunohistochemistry; Medulloblastoma; Pediatric; Subtype

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; KI 67 ANTIGEN; NERVE CELL ADHESION MOLECULE; NERVE GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN S 100; SYNAPTOPHYSIN;

ADOLESCENT; ANAPLASTIC CARCINOMA; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MEDULLOBLASTOMA; NEUROFILAMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR CLASSIFICATION;

ADOLESCENT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEDULLOBLASTOMA; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037298420     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2003.01444.x     Document Type: Article

References (32)

1. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-25.
2. Burger PC, Grahmann FC, Bliestle A, Kleihues P. Differentiation in the medulloblastoma. A histological and immunohistochemical study. Acta Neuropathol 1987; 73: 115-23.
3. Giangaspero F, Chieco P, Ceccarelli C et al. 'Desmoplastic' versus 'classic' medulloblastoma: comparison of DNA content, histopathology and differentiation. Virchows Arch Pathol Anat Histopathol 1991; 418: 207-14.
4. Katsetos CD, Herman MM, Frankfurter A et al. Cerebellar desmoplastic medulloblastomas. A further immunohistochemical characterization of the reticulin-free pale islands. Arch Pathol Lab Med 1989; 113: 1019-29.
5. Giangaspero F, Perilongo G, Fondelli MP et al. Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 1999; 91: 971-77.
6. Giangaspero F, Rigobello L, Badiali M et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 1992; 16: 687-93.
7. Sure U, Berghorn WJ, Bertalanffy H et al. Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute. Acta Neurochir 1995; 132: 59-65.
8. Chatty EM, Earle KM. Medulloblastoma. A report of 201 cases with emphasis on the relationship of histologic variants to survival. Cancer 1971; 28: 977-83.
9. Park TS, Hoffman HJ, Hendrick EB, Humphreys RP, Becker LE. Medulloblastoma: clinical presentation and management. Experience at the hospital for sick children, Toronto. J Neurosurg 1983; 58: 543-52.
10. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997; 57: 3272-80.
11. Korshunov A, Golanov A, Ozerov S, Sycheva R. Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases. Brain Tumor Pathol 1999; 16: 37-44.
12. Eberhart CG, Kepner JL, Goldthwaite PT et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002; 94: 552-60.
13. McLendon RE, Friedman HS, Fuchs HE, Kun LE, Bigner SH. Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study. Histopathology 1999; 34: 154-62.
14. Jorgensen OS. Neural cell adhesion molecule (NCAM) as a quantitative marker in synaptic remodeling. Neurochem Res 1995; 20: 533-47.
15. Figarella-Branger DF, Durbec PL, Rougon GN. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors. Cancer Res 1990; 50: 6364-70.
16. Molenaar WM, de Leij L, Trojanowski JQ. Neuroectodermal tumors of the peripheral and the central nervous system share neuroendocrine N-CAM-related antigens with small cell lung carcinomas. Acta Neuropathol 1991; 83: 46-54.
17. Frost G, Patel K, Bourne S, Coakham HB, Kemshead JT. Expression of alternative isoforms of the neural cell adhesion molecule (NCAM) on normal brain and a variety of brain tumours. Neuropathol Appl Neurobiol 1991; 17: 207-17.
18. Baker DL, Molenaar WM, Trojanowski JQ et al. Nerve growth factor receptor expression in peripheral and central neuroectodermal tumors, other pediatric brain tumors, and during development of the adrenal gland. Am J Pathol 1991; 139: 115-22.
19. Tajima Y, Molina RP Jr, Rorke LB et al. Neurotrophins and neuronal versus glial differentiation in medulloblastomas and other pediatric brain tumors. Acta Neuropathol 1998; 95: 325-32.
20. Coffin CM, Braun JT, Wick MR, Dehner LP. A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression. Mod Pathol 1990; 3: 164-70.
21. Coffin CM, Mukai K, Dehner LP. Glial differentiation in medulloblastomas. Histogenetic insight, glial reaction, or invasion of brain? Am J Surg Pathol 1983; 7: 555-65.
22. Schindler E, Gullotta F. Glial fibrillary acidic protein in medulloblastomas and other embryonic CNS tumours of children. Virchows Arch Pathol Anat Histopathol 1983; 398: 263-75.
23. Molenaar WM, Trojanowski JQ. Primitive neuroectodermal tumors of the central nervous system in childhood: tumor biological aspects. Crit Rev Oncol Hematol 1994; 17: 1-25.
24. Szymas J, Biczysko W, Gabryel P, Morkowski S. Medulloblastoma: histological evaluation and prognosis. A clinical, immunohistochemical and electron microscopic study. Child Nerv Syst 1987; 3: 74-80.
25. Kimura T, Budka H, Soler-Federsppiel S. An immunocytochemical comparison of the glia-associated proteins glial fibrillary acidic protein (GFAP) and S-100 protein (S100P) in human brain tumors. Clin Neuropathol 1986; 5: 21-27.
26. Diebold J, Baretton G, Felchner M et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996; 105: 341-49.
27. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-36.
28. Eberhart CG, Kaufman WE, Tihan T, Burger PC. Apoptosis, neuronal maturation, and neurotrophin expression within medulloblastoma nodules. J Neuropathol Exp Neurol 2001; 60: 462-69.
29. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-15.
30. Schiffer D, Cavalla P, Chio A et al. Tumor cell proliferation and apoptosis in medulloblastoma. Acta Neuropathol 1994; 87: 362-70.
31. Nam DH, Wang KC, Kim YM, Chi JG, Kim SK, Cho BK. The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. J Korean Med Sci 2000; 15: 452-56.
32. Woodburn RT, Azzarelli B, Montebello JF, Goss IE. Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol 2001; 52: 57-62.